BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Arvinas

Arvinas logo

Founded
2013
Geography
United States of America based
Funding
$111.600 M

Arvinas is a pharmaceutical company focused on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Central to Arvinas’ proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. This strategy of degradation versus protein inhibition holds several advantages including the potential to target proteins that are not currently ‘druggable’ using a small molecule approach.

Technologies

Protein Degraders Startups  


Posts Mentioning This Company

R&D Platform

-


Pipelines

ARV-110
Clinical  |  Visit website

Arvinas is developing ARV-110, a PROTAC® protein degrader that targets the androgen receptor (AR), for the potential treatment of men with metastatic castration resistant prostate cancer (mCRPC) and who have progressed on existing therapies.

Products

 

Services

No services posted yet